Myelofibrosis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 175 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myelofibrosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Myelofibrosis - Pipeline Review, H1 2015', provides an overview of the Myelofibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myelofibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Myelofibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Myelofibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myelofibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myelofibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Myelofibrosis Overview 9
Therapeutics Development 10
Pipeline Products for Myelofibrosis - Overview 10
Pipeline Products for Myelofibrosis - Comparative Analysis 11
Myelofibrosis - Therapeutics under Development by Companies 12
Myelofibrosis - Therapeutics under Investigation by Universities/Institutes 15
Myelofibrosis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Myelofibrosis - Products under Development by Companies 19
Myelofibrosis - Products under Investigation by Universities/Institutes 21
Myelofibrosis - Companies Involved in Therapeutics Development 22
Acceleron Pharma, Inc. 22
Bristol-Myers Squibb Company 23
Celgene Corporation 24
CTI BioPharma Corp. 25
Gilead Sciences, Inc. 26
Incyte Corporation 27
Italfarmaco S.p.A. 28
Johnson & Johnson 29
KaloBios Pharmaceuticals, Inc. 30
MEI Pharma, Inc. 31
Nippon Shinyaku Co., Ltd. 32
Novartis AG 33
Onconova Therapeutics, Inc. 34
Pfizer Inc. 35
PharmaEssentia Corporation 36
Promedior, Inc. 37
Stemline Therapeutics, Inc. 38
Threshold Pharmaceuticals, Inc. 39
Myelofibrosis - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
BMS-911543 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
buparlisib hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
erismodegib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
evofosfamide - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
givinostat - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
glasdegib - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
imetelstat sodium - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
INCB-39110 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
KB-004 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
LCL-161 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
momelotinib - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
NS-018 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pacritinib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
panobinostat - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
peginterferon alfa-2b - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
pomalidomide - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
pracinostat - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
PRM-151 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
rigosertib sodium - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
simtuzumab - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
SL-401 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
sotatercept - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Myelofibrosis - Recent Pipeline Updates 112
Myelofibrosis - Dormant Projects 162
Myelofibrosis - Discontinued Products 163
Myelofibrosis - Product Development Milestones 164
Featured News & Press Releases 164
Dec 09, 2014: CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells 164
Dec 09, 2014: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting 165
Dec 08, 2014: PRM-151 therapy well tolerated in patients with advanced myelofibrosis 166
Dec 06, 2014: CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers 167
Dec 02, 2014: Incyte To Present Data On INCB039110 At at the 2014 American Society of Hematology Annual Meeting 168
Dec 01, 2014: CTI BioPharma Announces Data Presentation at the 56th American Society of Hematology Annual Meeting 169
Nov 06, 2014: Promedior Announces Presentation of Phase 2 Data on PRM-151 in Myelofibrosis at the Upcoming ASH Annual Meeting 170
Nov 03, 2014: Geron Announces Removal of Full Clinical Hold on Imetelstat IND 171
Nov 03, 2014: Promedior Receives Fast Track Designation for PRM-151 for the Treatment of Myelofibrosis 171
Sep 02, 2014: Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Myelofibrosis 172
Appendix 174
Methodology 174
Coverage 174
Secondary Research 174
Primary Research 174
Expert Panel Validation 174
Contact Us 174
Disclaimer 175

List of Tables
Number of Products under Development for Myelofibrosis, H1 2015 10
Number of Products under Development for Myelofibrosis - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Myelofibrosis - Pipeline by Acceleron Pharma, Inc., H1 2015 22
Myelofibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 23
Myelofibrosis - Pipeline by Celgene Corporation, H1 2015 24
Myelofibrosis - Pipeline by CTI BioPharma Corp., H1 2015 25
Myelofibrosis - Pipeline by Gilead Sciences, Inc., H1 2015 26
Myelofibrosis - Pipeline by Incyte Corporation, H1 2015 27
Myelofibrosis - Pipeline by Italfarmaco S.p.A., H1 2015 28
Myelofibrosis - Pipeline by Johnson & Johnson, H1 2015 29
Myelofibrosis - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 30
Myelofibrosis - Pipeline by MEI Pharma, Inc., H1 2015 31
Myelofibrosis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 32
Myelofibrosis - Pipeline by Novartis AG, H1 2015 33
Myelofibrosis - Pipeline by Onconova Therapeutics, Inc., H1 2015 34
Myelofibrosis - Pipeline by Pfizer Inc., H1 2015 35
Myelofibrosis - Pipeline by PharmaEssentia Corporation, H1 2015 36
Myelofibrosis - Pipeline by Promedior, Inc., H1 2015 37
Myelofibrosis - Pipeline by Stemline Therapeutics, Inc., H1 2015 38
Myelofibrosis - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 39
Assessment by Monotherapy Products, H1 2015 40
Number of Products by Stage and Target, H1 2015 42
Number of Products by Stage and Mechanism of Action, H1 2015 44
Number of Products by Stage and Route of Administration, H1 2015 46
Number of Products by Stage and Molecule Type, H1 2015 48
Myelofibrosis Therapeutics - Recent Pipeline Updates, H1 2015 112
Myelofibrosis - Dormant Projects, H1 2015 162
Myelofibrosis - Discontinued Products, H1 2015 163